Coherus BioSciences, Inc. (Nasdaq: CHRS) announced an update to its CHS-1701 clinical program.“The recent pharmacokinetic/pharmacodynamic (PK/PD) study is acceptable to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE